The suit is expected to address the product Acthar Gel, which sells for $28,000 per dose. In 2005, the treatment cost $1,235. In a statement, the company said it entered into settlement agreement staff to fully resolve this matter subject to approval by the commission. The FTC said Mallinckrodt will pay $100 million to settle commission state charges related to allegations the company maintained monopoly of specialty drugs.